By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


SEARCH JOBS

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.


Key Statistics


Email:
Ownership: Public

Web Site: Ironwood
Employees:
Symbol: IRWD
 



Industry
Pharmaceutical






Company News
Ironwood (IRWD) To Present At 2016 UBS Global Healthcare Conference 5/19/2016 11:46:17 AM
Ironwood (IRWD) To Present Linaclotide Data At Digestive Disease Week 2016 5/17/2016 11:11:37 AM
Ironwood (IRWD) Provides First Quarter 2016 Investor Update 5/10/2016 12:00:30 PM
Ironwood (IRWD) To Present At Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 10:10:15 AM
Ironwood (IRWD) To Host First Quarter 2016 Investor Update Call 4/26/2016 11:17:14 AM
Ironwood (IRWD) to Fork Over Up to $256 Million Plus Royalties to AstraZeneca PLC (AZN) for U.S. Rights to Gout Drug 4/26/2016 5:43:18 AM
Ironwood (IRWD) Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis 4/5/2016 8:18:03 AM
Ironwood (IRWD) To Present Clinical And Preclinical Data On sGC Stimulators At Upcoming Scientific Conferences 3/30/2016 8:58:06 AM
Ironwood (IRWD) Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease 3/23/2016 9:55:11 AM
Ironwood (IRWD) To Present At Barclays Global Healthcare Conference 3/10/2016 10:28:22 AM
12345678910...
//-->